	Actif À Court Terme		Date
Acadia Pharmaceuticals	USD 1.08B	115.87M	2025-09
ALKERMES	USD 1.74B	106.38M	2025-09
Alnylam Pharmaceuticals	USD 4.05B	97.85M	2025-12
Biogen	USD 8.97B	37.5M	2025-12
BioMarin Pharmaceutical	USD 3.85B	49.21M	2025-09
Bristol-Myers Squibb	USD 35.63B	2.41B	2025-09
Cara Therapeutics	USD 43.13M	4.18M	2025-06
Corcept Therapeutics	USD 541.13M	98.02M	2025-09
Cytokinetics	USD 977.35M	90.81M	2025-09
Eisai	JPY 840.88B	50.18B	2025-12
Eli Lilly	USD 55.63B	6.44B	2025-12
Incyte	USD 5.02B	746.01M	2025-12
J&J	USD 55.62B	1.01B	2025-12
Moderna	USD 6.54B	54M	2025-12
Neurocrine Biosciences	USD 2.52B	364.3M	2025-12
Pfizer	USD 46.92B	3.22B	2025-09
Prothena	USD 339.97M	45.51M	2025-09
PTC Therapeutics	USD 2.27B	266.14M	2025-12
Sarepta Therapeutics	USD 2.72B	65.32M	2025-09
Ultragenyx Pharmaceutical	USD 643.21M	76.58M	2025-09
Vanda Pharmaceuticals	USD 347.26M	20.23M	2025-12
Vertex Pharmaceuticals	USD 11.2B	631.4M	2025-12

Acadia Pharmaceuticals Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.